What makes an antipsychotic 'atypical'?: Should the definition be preserved?

CNS Drugs

Volumn 7, Issue 5, 1997, Pages 347-348

  Kane, John M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; SERTINDOLE;

DRUG EFFECT; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; NOTE; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0030900280     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199707050-00002     Document Type: Note

References (4)

1. Klein DF, Davis JM. Diagnosis and drug treatment of psychotic disorders. Baltimore (MD): Williams & Wilkins, 1969
2. Janicak PG, Davis JM, Preskorn SH, et al. Principles and practice of psychopharmacotherapy. Baltimore (MD): Williams & Wilkins, 1993: 104-6
3. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind commparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96
4. Waddington JL, O'Callaghan E. What makes an antipsychotic 'atypical': conserving the definition. CNS Drugs 1997 May; 7 (5): 341-6